Skip to main content
Fig. 5 | BMC Urology

Fig. 5

From: Expression patterns of the immune checkpoint ligand CD276 in urothelial carcinoma

Fig. 5

Expression of CD276 in bladder tumors in different tumor stages. a Bladder tumor samples from patients at stages T2a to T4b were investigated for CD276 expression and are presented as function of the clinical tumor stage. The median CD276 expression peaked in stage T2b samples (score 210), slightly declined throughout later stages to drop in tumor tissue samples obtained from late-stage patients at T4b to a median score of 145. b Bladder tumor samples of patients in all stages were investigated for CD276 expression and correlated to the tumor stages < pT3a versus ≥ pT3a. Significant differences in expression of CD276 in < pT3a (median score 190) versus ≥ pT3a tumors (median score 185; χ2 = 0.86) were not observed

Back to article page